Discover a study on psoriasis treatment failure, highlighting when to move from topical therapies to systemic care for ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque ...

Treatment with GLP-1 RAs was linked to decreased risks for all-cause mortality and MACE in patients with psoriasis when compared with other antidiabetic or obesity drugs.

Adhering to a Mediterranean diet significantly improved disease severity among patients with psoriasis, independent of weight ...

A groundbreaking technology developed by Heriot-Watt University has received over £475,000 in funding to revolutionize how ...

Anti-IL-17A biologics have the greatest odds of achieving and maintaining clear or almost clear skin among patients with psoriasis.

Long-term follow-up in such diseases as psoriasis and atopic dermatitis are reinforcing the empiric impression that a ‘super ...

The FDA has expanded Johnson & Johnson’s Tremfya (guselkumab) approval to children six years and older weighing at least 40 ...

Treatment with the IL-23 inhibitor significantly improved skin clearance in the pediatric study of children aged 6-17 with ...

Psoriasis may not have a cure, but new research has found that significant relief could be achieved at the dinner table. In a ...

Recent FDA approvals include new therapies for AD, HS, and plaque psoriasis, impacting patients with skin of color. Tapinarof cream, roflumilast foam, and delgocitinib are notable topical treatments ...